SMAD5 and cancer: Moreover, treatment with siRNA-SMAD5 induced a luminal CD44-/CD24+ phenotype in MDA-MB 231 cells (Figure 6B), indicating that SMAD5 expression is required to maintain a CD44+/CD24- cancer stem cell-like phenotype.